<img src="https://ml-eu.globenewswire.com/Resource/Download/f0161a05-9638-4da5-a4af-f9cdb28f0304?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Logo+Warm+Black+RGB.jpg" alt="Novartis Pharma AG"/><ul type="disc"><li style="margin-top:5pt; margin-bottom:8pt;">New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session </li><li style="margin-bottom:8pt;">New ianalumab interim results from Sjögren’s Phase III extension study up to week 108 and Phase II data in systemic lupus erythematosus will be presented </li></ul> Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases. “Novartis is committed to shaping the future of immunology. From small molecules to biologics and CAR-T cell therapy, our pioneering science is focused on where we can have the greatest impact on patient outcomes,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “At EULAR, we will share compelling new data for Cosentyx, ianalumab and our CAR-T therapy rap-cel across diseases where there is high unmet need. These data demonstrate how Novartis innovation can have meaningful impact for people living with autoimmune diseases like polymyalgia rheumatica, Sjogren’s disease, systemic lupus erythematosus and systemic sclerosis.” Key abstracts accepted by EULAR include: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;;border-bottom: solid black 1pt ; vertical-align: top ; "> Molecule/Disease </td><td style="max-width:60%; width:60%; min-width:60%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; "> Abstract Title </td><td style="max-width:25%; width:25%; min-width:25%;;border-bottom: solid black 1pt ; vertical-align: top ; "> Number/Presentation Details </td></tr><tr><td colspan="3" style="border-bottom: solid black 1pt ; vertical-align: top ; "> Cosentyx® (secukinumab) </td></tr><tr><td rowspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Polymyalgia Rheumatica   </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> OP0116 Oral Presentation June 3, 4:30pm-4:40pm BST </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Secukinumab in patients with polymyalgia rheumatica: Subgroup analyses of Week 52 results of a Phase 3, multicentre, randomised, double-blind, placebo-controlled trial (REPLENISH) </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> POS0019 Poster Tour Presentation June 3, 3:30pm-4:30pm BST </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Psoriatic Arthritis </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Impact of Early Biologic Use With Secukinumab on Radiographic Progression in Psoriatic Arthritis: A Pooled Analysis of the FUTURE 1 and FUTURE 5 Trials </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> POS0474 Poster Tour Presentation June 3, 3:30pm-4:50pm BST  </td></tr><tr><td colspan="3" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Rap-cel (rapcabtagene autoleucel, YTB323) </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Systemic Sclerosis and Severe Refractory Idiopathic Inflammatory Myopathies </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Safety and Early Efficacy of Rapcabtagene Autoleucel, an Autologous CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, in Severe Refractory Idiopathic Inflammatory Myopathies and Diffuse Cutaneous Systemic Sclerosis: Preliminary Analysis of the Open-Label AUTOGRAPH-IIM and –SSC studies </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> OP077 Oral Abstract Presentation June 3, 4:40pm-4:50pm BST </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Systemic Lupus Erythematosus </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 24 Months After Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> POS0303 Poster Tour Presentation June 5, 4:00pm-5:00pm BST </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Ianalumab </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">   </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">   </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Sjögren's Disease </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Efficacy and Safety of the Ianalumab Global Phase 3 Studies (NEPTUNUS-1 and NEPTUNUS-2) and Their Extension Study in Patients With Sjögren's Disease </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> OP0126 Oral Presentation June 3, 4:50pm-5:00pm BST </td></tr><tr><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Systemic Lupus Erythematosus </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> Safety and Efficacy of Subcutaneous Ianalumab (VAY736) Post-B Cell Recovery in Patients with Systemic Lupus Erythematosus: End of Study Results from a Phase 2 Study </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; "> OP0335 Oral Presentation June 5, 8:15am-8:25am BST </td></tr></table> About Novartis Immunology  At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. Product Information For full prescribing information, including approved indications and important safety information about marketed products, please visit <a href="https://www.novartis.com/about/products" rel="nofollow" target="_blank" title="">https://www.novartis.com/about/products</a>. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at <a href="https://www.novartis.com/" rel="nofollow" target="_blank" title="">https://www.novartis.com</a> and connect with us on <a href="https://www.linkedin.com/company/novartis/" rel="nofollow" target="_blank" title="">LinkedIn</a>, <a href="https://www.facebook.com/novartis/" rel="nofollow" target="_blank" title="">Facebook</a>, <a href="https://twitter.com/Novartis" rel="nofollow" target="_blank" title="">X/Twitter</a> and <a href="https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$" rel="nofollow" target="_blank" title="">Instagram</a>. # # # <table style="border-collapse: collapse; border-collapse:collapse ;"><tr><td style="width:338px;;vertical-align: top ; "> Novartis Media Relations E-mail: <a href="mailto:media.relations@novartis.com" rel="nofollow" target="_blank" title="media.relations@novartis.com">media.relations@novartis.com</a> </td><td style="width:336px;;vertical-align: top ; "> </td></tr><tr><td style="width:338px;;vertical-align: top ; "> Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: <a href="mailto:investor.relations@novartis.com" rel="nofollow" target="_blank" title="investor.relations@novartis.com">investor.relations@novartis.com</a> </td><td style="width:336px;;vertical-align: top ; ">   </td></tr></table> <img alt="" src='https://ml-eu.globenewswire.com/media/ZDA5NTliMDQtZWJjYS00YTkzLWI1YzYtOWUyMDE4M2NkMmY4LTEwMTQwMjQtMjAyNi0wNi0wMS1lbg==/tiny/Novartis-Pharma-AG.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn